collaborators

1 paper

stat.ME2025

Cure Rate Joint Model for Time-to-Event Data and Longitudinal Tumor Burden with Potential Change Points

Yixiang Qu, Ethan M. Alt, Weibin Zhong +3

In non-small cell lung cancer (NSCLC) clinical trials, tumor burden (TB) is a key longitudinal biomarker for assessing treatment effects. Typically, standard-of-care (SOC) therapie…